On January 29, 2026 Immuto Scientific reported a collaborative agreement with the University of Wisconsin–Madison to identify disease-specific, novel therapeutic targets in colorectal cancer using Immuto’s proprietary structural surfaceomics platform. The collaboration, led at UW by Dustin Deming, M.D., professor of medicine and leading expert in colorectal cancer, provides Immuto Scientific with access to uniquely characterized patient-derived organoid models representing microsatellite stable colorectal cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our work with Dr. Deming and the University of Wisconsin–Madison represents an exceptional opportunity to study colorectal cancer in a clinically relevant form," said Faraz A. Choudhury, Ph.D., co-founder and CEO of Immuto Scientific. "By integrating patient-derived models with our structural surfaceomics platform, we can reveal previously unseen, disease-specific surface structures for drug targets that open new possibilities for therapeutic intervention."
Through this multi-year research effort, Immuto will apply its high-resolution structural proteomics and AI-enabled analytics to interrogate conformational differences in cell-surface proteins between tumor and normal tissues. These insights will support the company’s discovery of disease-specific surface protein conformations (SPCs), a new class of therapeutic targets that could enable safer and more precise treatments for solid tumors.
"Our collection of patient-derived colorectal cancer organoids enables exploration of tumor biology and therapeutic vulnerabilities in ways that traditional models cannot," said Deming, who is also a member of the UW Carbone Cancer Center. "Through this collaboration with Immuto Scientific, we aim to identify new molecular targets that may ultimately improve treatment options for patients."
This collaborative agreement builds on Immuto’s growing network of academic and industry collaborations designed to accelerate discovery of a novel class of structural, disease-specific targets invisible to conventional genomics or proteomics approaches. Immuto’s platform integrates live-cell structural proteomics and AI-driven conformational analytics to map the three-dimensional architecture of the cell surface proteome to reveal an undiscovered druggable space of SPCs.
(Press release, Immuto Scientific, JAN 29, 2026, View Source [SID1234662362])